Pharmacokinetics of paclitaxel administered in combination with cisplatin, etoposide and bleomycin in patients with advanced solid tumours

Cancer Chemotherapy and Pharmacology

Volumn 44, Issue 4, 1999, Pages 349-353

  Nannan Panday, Vinodh R ^a,d   De Wit, Ronald ^b   Schornagel, Jan H ^a   Schot, Margaret ^a   Rosing, Hilde ^d   Lieverst, Jan ^a   Ten Bokkel Huinink, Wim W ^a   Schellens, Jan H M ^a   Beijnen, Jos H ^a,c,d  

^a ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^b ERASMUS MC CANCER INSTITUTE   (Netherlands)

^c UTRECHT UNIVERSITY   (Netherlands)

^d SLOTERVAART HOSPITAL   (Netherlands)

Author keywords

Bleomycin; Cisplatin; Etoposide; Paclitaxel; Pharmacokinetics

Indexed keywords

BLEOMYCIN; CISPLATIN; ETOPOSIDE; PACLITAXEL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; ADVANCED CANCER; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; HUMAN; MULTICENTER STUDY; PHARMACOKINETICS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SOLID TUMOR;

ADENOCARCINOMA; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; CARCINOMA; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ETOPOSIDE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; MIDDLE AGED; NEOPLASMS; PACLITAXEL;

EID: 0032810997     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050988     Document Type: Article

References (23)

1. Bokemeyer C, Beyer J, Metzner B, Rüther U, Harstrick A, Weissbach L, Köhrmann U, Verbeek W, Schmoll H-J (1996a) Phase II study of paclitaxel in patients with relapsed or cisplatin-refractory testicular cancer. Ann Oncol 7: 31
2. Bokemeyer C, Hartmann JT, Kuczyk MA, Truss MC, Beyer J, Jonas U, Kanz L (1996b) The role of paclitaxel in chemosensitive urological malignancies: current strategies in bladder cancer and testicular germ-cell tumours. World J Urol 14: 354
3. Chou T-C, Motzer RJ, Tong Y, Bosl GJ (1994) Computerized quantitation of synergism and antagonism of Taxol, topotecan, and cisplatin against human-teratocarcinoma cell growth: a rational approach to clinical protocol design. J Natl Cancer Inst 86: 1517
4. Droz JP, Culine S, Biron P, Kramar A (1996) High-dose chemotherapy in germ-cell tumors. Ann Oncol 7: 997
5. Einhorn LH (1990) Treatment of testicular cancer: a new and improved model. J Clin Oncol 8: 1777
6. Ellis AG, Crinis NA, Webster LK (1996) Inhibition of etoposide elimination in the isolated perfused rat liver by Cremphor EL and Tween 80. Cancer Chemother Pharmacol 38: 81
7. Greco FA, Hainsworth JD (1994) Poorly differentiated carcinoma or adenocarcinoma of unknown primary site: long-term results with cisplatin-based chemotherapy. Semin Oncol 21 [5 Suppl 12]: 77
8. Horwich A, Sleijfer DT, Fossa SD, Kaye SB, Oliver RTD, Cullen MH, Mead GM, de Wit R, de Mulder PHM, Dearnaley DP, Cook PA, Sylvester RJ, Stenning SP (1997) Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminatous germ-cell cancer: a multi institutional Medical Research Council/European Organization for Research and Treatment of Cancer trial. J Clin Oncol 15: 1844
9. Huizing MT, Keung ACF, Rosing H, van der Kuij V, ten Bokkel Huinink WW, Mandjes I, Dubbelman AC, Pinedo HM, Beijnen JH (1993) Pharmacokinetics of paclitaxel metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients. J Clin Oncol 11: 2127
10. Huizing MT, Giaccone G, Van Warmerdam LJC, Rosing H, Bakker PJM, Vermorken JB, Postmus PE, Van Zandwijk M, Koolen MGJ, ten Bokkel Huinink WW, van der Vijgh WJF, Bierhorst FJ, Lai A, Dalesio O, Pinedo HM, Veenhof CHN, Beijnen JH (1997) Pharmacokinetics of paclitaxel and carboplatin in a dose-escalating and dose-sequencing study in patients with non-small cell lung cancer: an ECC trial. J Clin Oncol 15: 317
11. International Germ Cell Cancer Collaborative Group (1997) International germ cell consensus classification: a prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol 15: 594
12. Klaassen U, Harstrick A, Schleucher N, Vanhoefer U, Schroder J, Wilke H, Seeber S (1996) Activity- and schedule- dependent interactions of paclitaxel, etoposide and hydroxy-ifofamide in cisplatin-sensitive and -refractory human ovarian carcinoma cell lines. Br J Cancer 74: 224
13. Motzer RJ, Bajorin DF, Schwartz LH, Hutter HS, Bosl G, Scher HI, Lyn P, Fischer P (1994) Phase II trial of paclitaxel shows antitumour activity in patients with previously treated germ cell tumours. J Clin Oncol 12: 2277
14. Nannan Panday VR, Huizing MT, Willemse PHB, De Graeff A, ten Bokkel Huinink WW, Vermorken JB, Beijnen JH (1997) Hepatic metabolism of paclitaxel and its impact in patients with altered hepatic function. Semin Oncol 24 [4 Suppl 11]: 34
15. Relling MV, Nemec J, Schuetz EG, Sshuetz JD, Gonzalez FJ, Korzekwa KR (1994) O-Demethylation of epipodophyllotoxins is catalyzed by human cytochrome P450 3A4. Mol Pharmacol 45: 352
16. Rosell R, Felip E, Massuti B, Gonzàlez-Larriba JL, Benito D, López-Cabrerizo MP, Salamanca O, Camps C, Puerto-Pica J (1997) Sequence-dependent paclitaxel/etoposide phase II trial in patients with non-small cell lung cancer. Semin Oncol 24 [4 Suppl 12]: 56
17. Rowinsky EK, Donehower RC (1995) Paclitaxel (Taxol). N Engl J Med 332: 1005
18. Rowinsky EK, Gilbert M, McGuire WP, Noe DA, Grochow LB, Forastiere AA, Ettinger DS, Lubejko BG, Sartorius SE, Cornblath DR, Hendricks CB, Donehower RC (1991) Sequences of Taxol and cisplatin: a phase I and Pharmacologic study. J Clin Oncol 9: 1692
19. Van der Vijgh WJF (1991) Clinical pharmacokinetics of carboplatin. Clin Pharmacokinet 21: 242
20. Van Warmerdam LJC, van Tellingen O, Maes RAA, Beijnen JH (1995) Validated method for the determination of carboplatin in biological fluids by Zeeman Atomic Absorption Spectrometry. Fresenius J Anal Chem 351: 1820
21. WHO (1979) WHO handbook for reporting results of cancer treatment. WHO, Geneva
22. Williams SD, Birch R, Einhorn LH, Irwin L, Greco FA, Loehrer PJ (1987) Treatment of disseminated germ-cell tumours with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med 316: 1435
23. De Wit R, Louwerens M, de Mulder PHM, Schornagel J (1998) A dose finding study of paclitaxel (Taxol) added to fixed doses of bleomycin, etoposide, cisplatin (BEP) in patients with adverse prognosis germ cell cancer or carcinoma of unknown primary. Proc Am Soc Clin Oncol 17: 322A